Herbst Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Herbst group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Herbst Group Today - Breaking & Trending Today
Vinva Investment Management Ltd lifted its stake in Lululemon Athletica Inc. (NASDAQ:LULU – Free Report) by 137.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,005 shares of the apparel retailer’s stock after purchasing an additional 1,741 shares during the period. Vinva […] ....
Capital World Investors increased its holdings in shares of Lululemon Athletica Inc. (NASDAQ:LULU – Free Report) by 0.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,547,793 shares of the apparel retailer’s stock after purchasing an additional 14,112 shares during the period. Capital World Investors’ holdings in Lululemon Athletica were worth $791,371,000 […] ....
Steward Partners Investment Advisory LLC lifted its holdings in Lululemon Athletica Inc. (NASDAQ:LULU – Free Report) by 14.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 31,033 shares of the apparel retailer’s stock after purchasing an additional 4,001 shares during the period. Steward Partners Investment Advisory LLC’s […] ....
Sculati Wealth Management LLC decreased its holdings in shares of Lululemon Athletica Inc. (NASDAQ:LULU – Free Report) by 3.7% in the fourth quarter, HoldingsChannel reports. The fund owned 7,612 shares of the apparel retailer’s stock after selling 294 shares during the quarter. Lululemon Athletica makes up about 1.8% of Sculati Wealth Management LLC’s portfolio, making […] ....
HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on the company. StockNews.com downgraded Esperion Therapeutics from a strong-buy rating […] ....